Erratum: Diabetes and pregnancy: An endocrine society clinical practice guideline (Journal of Clinical Endocrinology and Metabolism (2013) 98:11 (4227-4249) DOI:10.1210/jc.2013-2465);Diabetes and pregnancy: An endocrine society clinical practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages 4227-4249

  Blumer, Ian ^a   Hadar, Eran ^b   Hadden, David R ^c   Jovanovič, Lois ^d   Mestman, Jorge H ^e   Murad, M Hassan ^f   Yogev, Yariv ^b  

^a Charles H Best Diabetes Centre   (Canada)

^b Helen Schneider Hospital for Women   (Israel)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FOLIC ACID; GLIBENCLAMIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; NICOTINIC ACID; THYROID PEROXIDASE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN;

ALBUMINURIA; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BREAST FEEDING; CARBOHYDRATE INTAKE; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; CONTRACEPTION; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DYSLIPIDEMIA; EVIDENCE BASED PRACTICE; EYE EXAMINATION; FEMALE; FIRST TRIMESTER PREGNANCY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRADING OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT, AND EVALUATION SYSTEM; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY FUNCTION TEST; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MATERNAL HYPERTENSION; MEDICAL SOCIETY; NEURAL TUBE DEFECT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COUNSELING; POSTPARTUM THYROIDITIS; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PUERPERIUM; RISK ASSESSMENT; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL;

EID: 84887465724     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-4124     Document Type: Erratum

References (236)

1. Institute of Medicine Dietary Reference Intakes: Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: National Academies Press; 2002.
2. Atkins D, Best D, Briss PA, et al Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
3. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93: 666-673.
4. Guyatt G, Oxman ED, Akl EA, et al. GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64: 383-394.
5. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979;28: 1039-1057.
6. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358: 1991-2002.
7. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97: 2543-2565.
8. Anwar A, Salih A, Masson E, Allen B, Wilkinson L, Lindow SW. The effect of pre-pregnancy counselling for women with pre-gestational diabetes on maternal health status. Eur J Obstet Gynecol Reprod Biol. 2011;155: 137-139.
9. Murphy HR, Roland JM, Skinner TC, et al. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: Benefits beyond glycemic control. Diabetes Care. 2010; 33: 2514-2520.
10. Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001;94: 435-444.
11. Dicker D, Feldberg D, Samuel N, Yeshaya A, Karp M, Goldman JA. Spontaneous abortions in patients with insulin-dependent diabetes mellitus: the effect of preconceptional diabetic control.AmJ Obstet Gynecol. 1988;158: 1161-1164.
12. Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA. Preconception management of insulin-dependent diabetes: improvement of pregnancy outcome. Obstet Gynecol. 1991;77: 846-849.
13. Holing EV. Preconception care of women with diabetes: the unrevealed obstacles. J Matern Fetal Med. 2000;9: 10-13.
14. InksterME,Fahey TP,DonnanPT, Leese GP, Mires GJ,MurphyDJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes: systematic review of observational studies. BMC Pregnancy Childbirth. 2006;6:30.
15. Nielsen GL, Møller M, Sørensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006;29: 2612-2616.
16. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of womenwith prepregnancy diabetes. Diabetes Care. 2007;30:1920- 1925.
17. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes. Diabetologia. 2000;43: 79-82.
18. Bell R, Glinianaia SV, Tennant PW, Bilous RW, Rankin J. Periconception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. [published online ahead of print April 1, 2012]. Diabetologia. doi:10.1007/s00125-012-2455- y.
19. Langer O, Conway DL. Level of glycemia and perinatal outcome in pregestational diabetes. J Matern Fetal Med. 2000;9: 35-41.
20. JensenDM,Korsholm L, Ovesen P, et al. Peri-conceptionalA1Cand risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009;32: 1046-1048.
21. Persson B, Hansson U. Hypoglycaemia in pregnancy. Baillieres Clin Endocrinol Metab. 1993;7: 731-739.
22. Rosenn BM, Miodovnik M, Holcberg G, Khoury JC, Siddiqi TA. Hypoglycemia: the price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obstet Gynecol. 1995;85: 417-422.
23. Evers IM, ter Braak EW, de Valk HW, van Der Schoot B, Janssen N, Visser GH. Risk indicators predictive for severe hypoglycemia during the first trimester of Type 1 diabetic pregnancy. Diabetes Care. 2002;25: 554-559.
24. Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care. 2008;31: 9-14.
25. Robertson H, Pearson DW, Gold AE. Severe hypoglycaemia during pregnancy in women with type 1 diabetes is common and planning pregnancy does not decrease the risk. Diabet Med. 2009;26: 824-826.
26. Confidential Enquiry into Maternal and Child Health (CEMACH). Diabetes in Pregnancy: AreWeProviding the Best Care? Findings of a National Enquiry: England, Wales and Northern Ireland. London, UK: CEMACH; 2007.
27. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol. 1996;174: 1343-1353.
28. Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, Hansen AS, Mersebach H; Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin. Obstet Gynecol. 2008;198:186.e1-e7.
29. Mathiesen ER, Kinsley B, Amiel SA, et al; Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007;30: 771-776.
30. Lapolla A, DalfràMG,Spezia R, et al. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol. 2008;45: 61-66.
31. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23: 639-643.
32. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26: 590-596.
33. Gallen IW, Jaap A, Roland JM, Chirayath HH. Survey of glargine use in 115 pregnant women with type 1 diabetes. Diabet Med. 2008; 25: 165-169.
34. Lapolla A, Di Cianni G, Bruttomesso D, et al. Use of insulin detemir in pregnancy: a report on 10 type 1 diabetic women. Diabet Med. 2009;26: 1181-1182.
35. Pöyhönen-AlhoM,Rönnemaa T, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand. 2007;86: 1171-1174.
36. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care. 2010;33: 29-33.
37. Mathiesen ER, Hod M, Ivanisevic M, et al; Detemir in Pregnancy Study Group. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir withNPHinsulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012; 35: 2012-2017.
38. Wilson RD, Johnson JA, Wyatt P, et al; Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada and The Motherrisk Program. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2007;29:1003- 1026.
39. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000;23: 1084-1091.
40. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18: 631-637.
41. Vestgaard M, Ringholm L, Laugesen CS, Rasmussen KL, Damm P, Mathiesen ER. Pregnancy-induced sight-threatening diabetic retinopathy in women with type 1 diabetes. Diabet Med. 2010;27: 431-435.
42. Omori Y, Jovanovic L. Proposal for the reconsideration of the definition of gestational diabetes. Diabetes Care. 2005;28: 2592-2593.
43. Cundy T, Slee F, Gamble G, Neale L. Hypertensive disorders of pregnancy in women with type 1 and type 2 diabetes. Diabet Med. 2002;19: 482-489.
44. Rosenn B, Miodovnik M, Kranias G, et al. Progression of diabetic retinopathy in pregnancy: association with hypertension in pregnancy. Am J Obstet Gynecol. 1992;166: 1214-1218.
45. Lövestam-Adrian M, Agardh CD, Aberg A, Agardh E. Pre-eclampsia is a potent risk factor for deterioration of retinopathy during pregnancy in type 1 diabetic patients. Diabet Med. 1997;14:1059- 1065.
46. SibaiBM,Caritis S, Hauth J, et al. Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol. 2000;182: 364-369.
47. Ekbom P, Damm P, Feldt-Rasmussen B, Feldt-Rasmussen U, Mølvig J, Mathiesen ER. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care. 2001;24:1739- 1744.
48. Dunne FP, Chowdhury TA, Hartland A, et al. Pregnancy outcome in women with insulin-dependent diabetes mellitus complicated by nephropathy. QJM. 1999;92: 451-454.
49. Leguizamon G, Reece EA. Effect of medical therapy on progressive nephropathy: influence of pregnancy, diabetes and hypertension. J Matern Fetal Med. 2000;9: 70-78.
50. Biesenbach G, Grafinger P, Stöger H, Zazgornik J. How pregnancy influences renal function in nephropathic type 1 diabetic women depends on their pre-conceptional creatinine clearance. J Nephrol. 1999;12: 41-46.
51. Gordon M, Landon MB, Samuels P, Hissrich S, Gabbe SG. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstet Gynecol. 1996;87: 401-409.
52. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354: 2443-2451.
53. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev. 2006;82: 23-28.
54. Velázquez-Armenta EY. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy. 2007;26: 51-66.
55. Bullo M, Tschumi S, Bucher B. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60: 444-450.
56. Magee LA, von Dadelszen P, Bohun CM, et al. Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study. J Obstet Gynaecol Can. 2003;25: 372-382.
57. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013;36(Suppl 1):S11-S66.
58. Silfen SL, Wapner RJ, Gabbe SG. Maternal outcome in class H diabetes mellitus. Obstet Gynecol. 1980;55: 749-751.
59. Bagg W, Henley PG, Macpherson P, Cundy TF. Pregnancy in womenwith diabetes and ischaemic heart disease.AustNZJObstet Gynaecol. 1999;39: 99-102.
60. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll Cardiol. 2008;52: 171-180.
61. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A. 2004;131: 287-298.
62. Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can. 2007;29: 906-908.
63. Alvarez-Marfany M, Roman SH, Drexler AJ, Robertson C, Stagnaro- Green A. Long term prospective study of postpartum thyroid dysfunction in women with insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1994;79: 10-16.
64. Umpierrez GE, Latif KA, Murphy MB, et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care. 2003;26: 1181-1185.
65. Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005;105: 239-245.
66. Glinoer D, Soto MF, Bourdoux P, et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1991;73: 421-427.
67. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341: 549-555.
68. Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol. 1993;81: 349-353.
69. Man EB, Brown JF, Serunian SA. Maternal hypothyroxinemia: psychoneurological deficits of progeny. Ann Clin Lab Sci. 1991;21: 227-239.
70. International Association of Diabetes and Pregnancy Study Groups Consensus Panel; Metzger BE, Gabbe SG, Persson B, et al. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33: 676-682.
71. Prutsky G, Domecq, Elriayah T, et al. Screening of gestational diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98: 0000-0000.
72. Landon MB, Spong CY, Thom E, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal- Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes.NEngl J Med. 2009; 361: 1339-1348.
73. Pettitt DJ, Knowler WC, Baird HR, Bennett PH. Gestational diabetes: Infant and maternal complications of pregnancy in relation to third-trimester glucose tolerance in the Pima Indians. Diabetes Care. 1980;3: 458-464.
74. Jensen DM, Korsholm L, Ovesen P, Beck-Nielsen H, Mølsted-Pedersen L, Damm P. Adverse pregnancy outcome in women with mild glucose intolerance: is there a clinically meaningful threshold value for glucose? Acta Obstet Gynecol Scand. 2008;87: 59-62.
75. Sermer M, Naylor CD, Gare DJ, et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecol. 1995;173: 146-156.
76. Sacks DA, Greenspoon JS, Abu-Fadil S, Henry HM, Wolde-Tsadik G, Yao JF. Toward universal criteria for gestational diabetes: the 75-gram glucose tolerance test in pregnancy. Am J Obstet Gynecol. 1995;172: 607-614.
77. Ferrara A, Weiss NS, Hedderson MM. Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia. Diabetologia. 2007;50: 298-306.
78. Committee opinion no. 504: screening and diagnosis of gestational diabetes mellitus. Obstet Gynecol. 2011;118: 751-753.
79. National Institutes of Health Consensus Development Conference Statement: National Institutes of Health Consensus Development Conference Diagnosing Gestational Diabetes Mellitus March 4-6 2013. Bethesda, MD: National Institutes of Health; 2013.
80. HAPOStudy Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes. 2009;58: 453-459.
81. Metzger BE, Rabinkar V, Vileisis RA, Freinkel N. 'Accelerated starvation' and the skipped breakfast in late normal pregnancy. Lancet. 1982;i: 588-592.
82. Silverman BL, Rizzo TA, Cho NH, Metzger BE. Long-term effects of the intrauterine environment: the Northwestern University Diabetes in Pregnancy Center. Diabetes Care. 1998;21(Suppl 2):B142- B149.
83. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352: 2477-2486.
84. Short KR, Pratt LV, Teague AM, Man CD, Cobelli C. Postprandial improvement in insulin sensitivity after a single exercise session in adolescents with low aerobic fitness and physical activity. Pediatr Diabetes. 2013;14: 129-137.
85. Short KR, Pratt LV, Teague AM. The acute and residual effect of a single exercise session on meal glucose tolerance in sedentary young adults. J Nutr Metab. 2012;2012:278678.
86. Young JC, Treadway JL. The effect of prior exercise on oral glucose tolerance in late gestational women. Eur J Appl Physiol Occup Physiol. 1992;64: 430-433.
87. AveryMD,Walker AJ. Acute effect of exercise on blood glucose and insulin levels in women with gestational diabetes. J Matern Fetal Med. 2001;10: 52-58.
88. Jovanovic-Peterson L, Durak EP, PetersonCM.Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol. 1989;161: 415-419.
89. O'Sullivan JB, Gellis SS, Dandrow RV, Tenney BO. The potential diabetic and her treatment in pregnancy. Obstet Gynecol. 1966;27: 683-689.
90. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358: 2003-2015.
91. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343: 1134-1138.
92. Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA. Predicting future diabetes in Latino women with gestational diabetes. Utility of early postpartum glucose tolerance testing. Diabetes. 1995;44: 586-591.
93. Pallardo F, Herranz L, Garcia-Ingelmo T, et al. Early postpartum metabolic assessment in women with prior gestational diabetes. Diabetes Care. 1999;22: 1053-1058.
94. Lauenborg J, Hansen T, Jensen DM, et al. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care. 2004;27: 1194-1199.
95. Kousta E, Efstathiadou Z, Lawrence NJ, et al. The impact of ethnicity on glucose regulation and the metabolic syndrome following gestational diabetes. Diabetologia. 2006;49: 36-40.
96. Bo S, Monge L, Macchetta C, et al. Prior gestational hyperglycemia: a long-term predictor of the metabolic syndrome. J Endocrinol Invest. 2004;27: 629-635.
97. Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a Danish population ofwomenwith previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab. 2005;90: 4004-4010.
98. Schaefer-Graf UM, Buchanan TA, Xiang AH, Peters RK, Kjos SL. Clinical predictors for a high risk for the development of diabetes mellitus in the early puerperium in women with recent gestational diabetes mellitus. Am J Obstet Gynecol. 2002;186: 751-756.
99. Holt RI, Goddard JR, Clarke P, Coleman MA. A postnatal fasting plasma glucose is useful in determining which women with gestational diabetes should undergo a postnatal oral glucose tolerance test. Diabet Med. 2003;20: 594-598.
100. Löbner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes. 2006;55: 792-797.
101. Wein P, Beischer NA, Sheedy MT. Studies of postnatal diabetes mellitus in women who had gestational diabetes. Part 2. Prevalence and predictors of diabetes mellitus after delivery.AustNZJObstet Gynaecol. 1997;37: 420-423.
102. Linné Y, Barkeling B, Rössner S. Natural course of gestational diabetes mellitus: long term follow up of women in the SPAWN study. BJOG. 2002;109: 1227-1231.
103. Aberg AE, Jönsson EK, Eskilsson I, Eskilsson I, Landin-Olsson M, Frid AH. Predictive factors of developing diabetes mellitus in women with gestational diabetes. Acta Obstet Gynecol Scand. 2002;81: 11-16.
104. Järvelä IY, Juutinen J, Koskela P, et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care. 2006; 29: 607-612.
105. O'Sullivan JB. Diabetes mellitus after GDM. Diabetes. 1991; 40(Suppl 2): 131-135.
106. Stowers JM, Sutherland HW, Kerridge DF. Long range implications for the mother. The Aberdeen experience. Diabetes. 1985; 34: 106-110.
107. Damm P. Gestational diabetes mellitus and subsequent development of overt diabetes mellitus. Danish Med Bull. 1998;45: 495-509.
108. Pettitt DJ, McKenna S, McLaughlin C, Patterson CC, Hadden DR, McCance DR. Maternal glucose at 28 weeks of gestation is not associated with obesity in 2-year-old offspring: the Belfast Hyperglycemia and Adverse Pregnancy Outcome (HAPO) family study. Diabetes Care. 2010;33: 1219-1223.
109. Prutsky GJ, Domecq JP, Zhen W, et al. Glucose targets in pregnant womenwith diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98: 0000-0000.
110. Chen R, Yogev Y, Ben-Haroush A, Jovanovic L,HodM,PhillipM. Continuous glucose monitoring for the evaluation and improved control of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2003;14: 256-260.
111. McLachlan K, Jenkins A, O'Neal D. The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. Aust N Z J Obstet Gynaecol. 2007;47: 186-190.
112. Voelmle M, Gottlieb P, Ellis S, Wallace A, Gerard L. Fetal outcomes and improved A1c values in pregnant women with type 1 diabetes using real-time continuous glucose sensors. Diabetes. 2007;56:A117.
113. Buchanan TA, Kjos SL, MontoroMN,et al. Use of fetal ultrasound to select metabolic therapy for pregnancies complicated by mild gestational diabetes. Diabetes Care. 1994;17: 275-283.
114. Kjos SL, Schaefer-Graf U, Sardesi S, et al.Arandomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. Diabetes Care. 2001;24: 1904-1910.
115. American Diabetes Association. Summary and recommendations of the First International Conference-Workshop on Gestational Diabetes Mellitus. Diabetes Care. 1980 3: 499-501.
116. Frenkel N. Summary and recommendations of the Second International Workshop-Conference on Gestational Diabetes. Diabetes. 1985;34(Suppl 2):S123-S126.
117. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes. The Organizing Committee. Diabetes Care. 1998;21(Suppl 2):B161-B167.
118. Langer O. Maternal glycemic criteria for insulin therapy in gestational diabetes mellitus. Diabetes Care. 1998;21(Suppl 2):B91- B98.
119. Gunderson EP. Gestational diabetes and nutritional recommendations. Curr Diab Rep. 2004;4: 377-386.
120. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of noninsulin- dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc. 1995;95: 1009-1017.
121. Kulkarni K, Castle G, Gregory R, et al. Nutrition Practice Guidelines for Type 1 Diabetes Mellitus positively affect dietitian practices and patient outcomes. The Diabetes Care and Education Dietetic Practice Group. J Am Diet Assoc. 1998;98: 62-70.
122. Reader D, Splett P, Gunderson E. Impact of gestational diabetes mellitus nutrition practice guidelines implemented by registered dietitians on pregnancy outcomes. J Am Diet Assoc. 2006;106: 1426-1433.
123. American Dietetic Association. Nutrition Practice Guidelines for Gestational Diabetes [CD-ROM]. Chicago, IL: American Dietetic Association; 2002.
124. Gunderson EP, Murtaugh MA, Lewis CE, Quesenberry CP, West DS, Sidney S. Excess gains in weight and waist circumference associated with childbearing: The Coronary Artery Risk Development in Young Adults Study (CARDIA). Int J Obes Relat Metab Disord. 2004;28: 525-535.
125. Callaway LK, Prins JB, Chang AM, McIntyre HD. The prevalence and impact of overweight and obesity in an Australian obstetric population. Med J Aust. 2006;184: 56-59.
126. Crane JM, White J, Murphy P, Burrage L, Hutchens D. The effect of gestational weight gain by body mass index on maternal and neonatal outcomes. J Obstet Gynaecol Can. 2009;31: 28-35.
127. Tennant PW, Rankin J, Bell R. Maternal body mass index and the risk of fetal and infant death: a cohort study from the North of England. Hum Reprod. 2011;26: 1501-1511.
128. Bhattacharya S, Campbell DM, Liston WA, Bhattacharya S. Effect of body mass index on pregnancy outcomes in nulliparous women delivering singleton babies. BMC Public Health. 2007;7:168.
129. Magee MS, Knopp RH, Benedetti TJ. Metabolic effects of 1200- kcal diet in obese pregnant women with gestational diabetes. Diabetes. 1990;39: 234-240.
130. IOM (Institute of Medicine) and NRC (National Research Council). Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: The National Academies Press; 2009.
131. Snyder J. Gray-Donald K, Koski KG. Predictors of infant birth weight in gestational diabetes. Am J Clin Nutr. 1994;59:1409- 1414.
132. Knopp RH, Magee MS, Raisys V, Benedetti T, Bonet B. Hypocaloric diets and ketogenesis in the management of obese gestational diabetic women. J Am Coll Nutr. 1991;10: 649-667.
133. Algert S, Shragg P, HollingsworthDR.Moderate caloric restriction in obese women with gestational diabetes. Obstet Gynecol. 1985; 65: 487-491.
134. Rizzo T, Metzger BE, Burns WJ, Burns K. Correlations between antepartum maternal metabolism and child intelligence. N Engl J Med. 1991;325: 911-916.
135. Jovanovic L, Metzger B, Knopp RH, et al. The Diabetes in Early Pregnancy Study:β-hydroxybutyrate levels in type 1 diabetic pregnancy compared with normal pregnancy. NICHD-Diabetes in Early Pregnancy Study Group (DIEP). National Institute of Child Health and Development. Diabetes Care November. 1998;21: 1978-1984.
136. American Diabetes Association. American Diabetes Association: gestational diabetes (position statement). Diabetes Care. 2000; 23(Suppl 1):S77-S79.
137. American Diabetes Association. Gestational diabetes. Diabetes Care. 2004;27(Suppl 1):S88 -S90.
138. Tieu J, Crowther CA, Middleton P. Dietary advice in pregnancy for preventing gestational diabetes. Cochrane Database Syst Rev. 2008;2:CD006674.
139. Fraser RB, Ford FA, Milner RD.Acontrolled trial of a high dietary fibre intake in pregnancy - effects on plasma glucose and insulin levels. Diabetologia. 1983;25: 238-241.
140. Jovanovic-Peterson L, PetersonCM,Reed GF, et al. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development-Diabetes in Early Pregnancy Study. Am J Obstet Gynecol. 1991;164: 103-111.
141. Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2003;26: 2261-2267.
142. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008;25: 442-449.
143. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47: 622-629.
144. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004;26: 724-736.
145. Mathiesen ER,DammP, Jovanovic L, et al. Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised, controlled trial in type 1 diabetes. Diabetes Metab Res Rev. 2011;27: 543-551.
146. Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG. 2007;114: 453-457.
147. Fang YM, MacKeen D, Egan JF, Zelop CM. Insulin glargine compared with neutral protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med. 2009;22: 249-253.
148. Smith JG,ManuckTA, White J, Merrill DC. Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy. Am J Perinatol. 2009;26: 57-62.
149. Egerman RS, Ramsey RD, Kao LW, et al. Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol. 2009;26: 591-595.
150. Imbergamo MP, Amato MC, Sciortino G, et al. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther. 2008;30: 1476-1484.
151. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49: 999-1005.
152. Lauszus FF. The clinical significance of IGF-I in maternal serum during pregnancy in type 1 diabetes. Curr Diabetes Rev. 2007;3: 194-197.
153. Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I inIDDMStudy Group. RhIGF-I inIDDMStudy Group. Diabetes Care. 1999;22: 585-592.
154. Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol. 2002;21: 181-189.
155. Lepercq J, Jacqueminet S, Hieronimus S, Timsit J, Grimaldi A. Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes. Diabetes Metab. 2010;36: 209-212.
156. Negrato CA, Rafacho A, Negrato G, et al. Glargine vs.NPHinsulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract. 2010;89: 46-51.
157. Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ. An estimation of the long-term clinical and economic benefits of insulin lispro in type 1 diabetes in the UK. Diabet Med. 2009;26: 803-814.
158. Loukovaara S, Immonen I, Teramo KA, Kaaja R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care. 2003;26: 1193-1198.
159. Durnwald CP, Landon MB. A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. J Matern Fetal Neonatal Med. 2008;21: 309-313.
160. Bhattacharyya A, Brown S, Hughes S, Vice PA. Insulin lispro and regular insulin in pregnancy. QJM. 2001;94: 255-260.
161. Aydin Y, Berker D, Direktör N, et al. Is insulin lispro safe in pregnant women: does it cause any adverse outcomes on infants or mothers? Diabetes Res Clin Pract. 2008;80: 444-448.
162. Persson B, Swahn ML, Hjertberg R, Hanson U, Nord E, Nordlander E, Hansson LO. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2002; 58: 115-121.
163. Cypryk K, Sobczak M, Pertyska-Marczewska M, et al. Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit. 2004;10:PI29-P132.
164. Wyatt JW, Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med. 2005;22: 803-807.
165. Bhattacharyya A, Vice PA. Insulin lispro, pregnancy, and retinopathy. Diabetes Care. 1999;22: 2101-2104.
166. Buchbinder A, Miodovnik M, McElvy S, et al. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy? Am J Obstet Gynecol. 2000;183: 1162-1165.
167. Hiéronimus S, Cupelli C, Bongain A, Durand-Réville M, Berthier F, Fénichel P. Pregnancy in type 1 diabetes: insulin pump versus intensified conventional therapy [in French]. Gynecol Obstet Fertil. 2005;33: 389-394.
168. Lapolla A, Dalfrà MG, Masin M, et al. Analysis of outcome of pregnancy in type 1 diabetics treated with insulin pump or conventional insulin therapy. Acta Diabetol. 2003;40: 143-149.
169. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes. Cochrane Database Syst Rev. 2010;1: CD005103.
170. Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol. 2007;197: 447-456.
171. Gabbe SG. New concepts and applications in the use of the insulin pump during pregnancy. J Matern Fetal Med. 2000;9: 42-45.
172. Simmons D, Thompson CF, Conroy C, Scott DJ. Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community. Diabetes Care. 2001; 24: 2078-2082.
173. Chen R, Ben-Haroush A, Weissmann-Brenner A, Melamed N, Hod M, Yogev Y. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol. 2007;197:404.e1-e5.
174. Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol. 2004;190: 1438-1439.
175. Jacobson GF,RamosGA,Ching JY, Kirby RS, Ferrara A, FieldDR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol. 2005;193: 118-124.
176. Ramos GA, Jacobson GF, Kirby RS, Ching JY, Field DR. Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol. 2007;27: 262-267.
177. Lain KY, Garabedian MJ, Daftary A, Jeyabalan A. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol. 2009; 200: 501-506.
178. Hebert MF, Ma X, Naraharisetti SB, et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009;85: 607-614.
179. Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemia agents vs insulin in management of gestational diabetes: a systemic review and metaanalysis. Am J Obstet Gynecol. 2009;203:457.e1-e9.
180. Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med. 2004;15: 51-55.
181. Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol. 2006; 195: 1090-1094.
182. Yogev Y, Melamed N, Chen R, Nassie D, Pardo J, Hod M. Glyburide in gestational diabetes - prediction of treatment failure. J Matern Fetal Neonatal Med. 2011;24: 842-842.
183. Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour LA. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet Gynecol. 2006;107: 1303-1309.
184. Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinatol. 2004;24: 617-622.
185. Goetzl L, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J Perinatol. 2002;22: 403-406.
186. Gutzin SJ, Kozer E, Magee LA, Feig DS, Koren G. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a metaanalysis. Can J Clin Pharmacol. 2003;10: 179-183.
187. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82: 893-902.
188. Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ. 2007;176: 933-938.
189. Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond Engl). 2010;6: 577-593.
190. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med. 2004;21: 829-836.
191. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006; 86: 658-663.
192. Salvesen KA, Vanky E, Carlsen SM. Metformin treatment in pregnant women with polycystic ovary syndrome-is reduced complication rate mediated by changes in the uteroplacental circulation? Ultrasound Obstet Gynecol. 2007;29: 433-437.
193. Bolton S, Cleary B, Walsh J, Dempsey E, Turner MJ. Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. Eur J Pediatr. 2009;168: 203-206.
194. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006; 28: 67-72.
195. Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010;38: 833-840.
196. Balsells M, Corcoy R, Adelantado JM, García-Patterson A, Altirriba O, de Leiva A. Gestational diabetes mellitus: metabolic control during labour. Diabetes Nutr Metab. 2000;13: 257-262.
197. Andersen O, Hertel J, Schmølker L, Kühl C. Influence of the maternal plasma glucose concentration at delivery on the risk of hypoglycaemia in infants of insulin-dependent diabetic mothers. Acta Paediatr Scand. 1985;74: 268-273.
198. MiodovnikM,Mimouni F, Tsang RC. Management of the insulindependent diabetic during labor and delivery. Influences on neonatal outcome. Am J Perinatol. 1987;4: 106-114.
199. Curet LB, Izquierdo LA, Gilson GJ, Schneider JM, Perelman R, Converse J. Relative effects of antepartum and intrapartum maternal blood glucose levels on incidence of neonatal hypoglycemia. J Perinatol. 1997;17: 113-115.
200. Lean ME, Pearson DW, Sutherland HW. Insulin management during labour and delivery in mothers with diabetes. Diabet Med. 1990;7: 162-164.
201. Feldberg D, Dicker D, Samuel N, Peleg D, Karp M, Goldman JA. Intrapartum management of insulin-dependent diabetes mellitus (IDDM) gestants. A comparative study of constant intravenous insulin infusion and continuous subcutaneous insulin infusion pump (CSIIP). Acta Obstet Gynecol Scand. 1988;67: 333-338.
202. Mimouni F. Perinatal asphyxia in infants of diabetic mothers is associated with maternal vasculopathy and hyperglycaemia in labour. Neonat Epidemiol Follow-up. 1987:400A.
203. Mayer-Davis EJ, Rifas-Shiman SL, Hu F, Colditz G, Gilman M. Breast feeding and risk for childhood obesity: does diabetes or obesity status matter? Diabetes Care October. 2006;2231-2237.
204. Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. Diabetes Care. 2006; 29: 1105-1107.
205. Gunderson EP. Breastfeeding after gestational diabetes pregnancy: subsequent obesity and type 2 diabetes in women and their offspring. Diabetes Care. 2007;30(Suppl 2):S161-S168.
206. Plagemann A, Harder T, Franke K, Kohlhoff R. Long-term impact of neonatal breast-feeding on body weight and glucose tolerance in children of diabetic mothers. Diabetes Care. 2002;25: 16-22.
207. Rodekamp E, Harder T, Kohlhoff R, Franke K, Dudenhausen JW, Plagemann A. Long-term impact of breast-feeding on body weight and glucose tolerance in children of diabetic mothers: role of the late neonatal period and early infancy. Diabetes Care. 2005;28: 1457-1462.
208. Mayer-Davis EJ, Rifas-Shiman SL, Zhou L, Hu FB, Colditz GA, Gillman MW. Breast-feeding and risk for childhood obesity: does maternal diabetes or obesity status matter? Diabetes Care. 2006; 29: 2231-2237.
209. Pettitt DJ, Forman MR, Hanson RL, Knowler WC, Bennett PH. Breastfeeding and incidence of non-insulin-dependent diabetes mellitus in Pima Indians. Lancet. 1997;350: 166-168.
210. Pettitt DJ, Knowler WC. Long-term effects of the intrauterine environment, birth weight, and breast-feeding in Pima Indians. Diabetes Care. 1998;21(Suppl 2):B138-B141.
211. Young TK, Martens PJ, Taback SP, Sellers EA, Dean HJ, Cheang M, Flett B. Type 2 diabetes mellitus in children: prenatal and early infancy risk factors among native Canadians. Arch Pediatr Adolesc Med. 2002;156: 651-655.
212. Virtanen SM, Räsänen L, Ylönen K, et al. Early introduction of dairy products associated with increased risk of IDDM in Finnish children. The Childhood in Diabetes in Finland Study Group. Diabetes. 1993;42: 1786-1790.
213. O'Reilly M, Avalos G, Dennedy MC, O'Sullivan EP, Dunne FP. Breast-feeding is associated with reduced postpartum maternal glucose intolerance after gestational diabetes. Ir Med J. 2012; 105(5 Suppl): 31-36.
214. Owen CG, Martin RM, Whincup PH, Smith GD, Cook DG. Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. Am J Clin Nutr. 2006;84: 1043-1054.
215. Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf. 2007;6: 191-198.
216. Glueck CJ, Salehi M, Sieve L, Wang P. Growth, motor, and social development in breast- and formula-fed infants of metformintreated women with polycystic ovary syndrome. J Pediatr. 2006; 148: 628-632.
217. Feig DS, Briggs GG, Kraemer JM, et al. Transfer of glyburide and glipizide into breast milk. Diabetes Care. 2005;28: 1851-1855.
218. GlatsteinMM,Djokanovic N, Garcia-Bournissen F, Finkelstein Y, Koren G. Use of hypoglycemic drugs during lactation. Can Fam Physician. 2009;55: 371-373.
219. Petersen KR, Skouby SO, Sidelmann J, Mølsted-Pedersen L, Jespersen J. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol. 1994;171: 400-405.
220. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA. 1994;271: 1099-1102.
221. Klein BE, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care. 1990;13: 895-898.
222. Skouby SO, Kühl C, Mølsted-Pedersen L, Petersen K, Christensen MS. Triphasic oral contraception: Metabolic effects in normal women and those with previous gestational diabetes. Am J Obstet Gynecol. 1985;153: 495-500.
223. Kjos SL, Shoupe D, Douyan S, et al. Effect of low dose oral contraceptives on carbohydrate metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study. Am J Obstet Gynecol. 1990;163: 1882-1827.
224. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA. 1998;280: 533-538.
225. Skouby SO, Andersen O, Saurbrey N, Kühl C. Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes. J Clin Endocrinol Metab. 1987;64: 519-523.
226. Creasy GW, Fisher AC, Hall N, Shangold GA. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. J Reprod Med. 2003;48: 179-186.
227. Weisberg E, Fraser IS, Lacarra M, et al. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception. 1999;59: 311-318.
228. Skouby SO, Mølsted-Pedersen L, Kosonen A. Consequences of intrauterine contraception in diabetic women. Fertil Steril. 1984; 42: 568-572.
229. Kimmerle R, Heinemann L, Berger M. Intrauterine devices are safe and effective contraceptives for type I diabetic women. Diabetes Care. 1995;18: 1506-1507.
230. Kjos SL, Ballagh SA, La Cour M, Xiang A, Mishekk DR Jr. The copper T380A intrauterine device in women with type II diabetes mellitus. Obstet Gynecol. 1994;84: 1006-1009.
231. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf. 1996;15: 430-440.
232. Rogovskaya S, Rivera R, Grimes DA, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol. 2005;105: 811-815.
233. Petersen KR. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull. 2002;49: 43-60.
234. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323: 1375-1381.
235. Kim CH, Ahn JW, Kang SP, Kim SH, Chae HD, Kang BM. Effect of levothyroxine treatment on in vitro fertilization and pregnancy outcome in infertile women with subclinical hypothyroidism undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2011;95: 1650-1654.
236. Bech K, Høier-Madsen M, Geldt-Rasmussen U, Jensen BM, Mølsted- Pedersen L, Kühl C. Thyroid dysfunction and autoimmune manifestations in insulin-dependent diabetes during and after pregnancy. Acta Endocrinol (Copenh). 1991;124: 534-539.